Picture loading failed.

Anti-TPBG therapeutic antibody (Pre-made Naptumomab biosimilar,Fab Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-363-1mg 1mg Inquiry
GMP-Bios-ab-363-10mg 10mg Inquiry
GMP-Bios-ab-363-100mg 100mg Inquiry
GMP-Bios-ab-363-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-TPBG therapeutic antibody (Pre-made Naptumomab biosimilar,Fab Fusion)
INN Name Naptumomab
FormatFab Fusion
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2006
Year Recommended2007
CompaniesActive Biotech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedNon-small cell lung cancer;Pancreatic cancer;Renal cancer
Development Techna